EU Annex 11 vs 21 CFR Part 11: What Is the Difference?
If you operate on both sides of the Atlantic, your computerised systems have to satisfy two regulations that want the same thing in slightly different ways: EU GMP Annex 11 and FDA 21 CFR Part 11. They overlap heavily, but they are not identical in scope, emphasis or language, and a system validated against one is not automatically compliant with the other. This guide compares them by theme and sets out the practical rule for satisfying both at once.
The short version
Both regulations govern the use of computerised systems and electronic records in a GxP environment. 21 CFR Part 11 is a US FDA regulation focused specifically on the trustworthiness of electronic records and electronic signatures. EU GMP Annex 11 is a European guideline on computerised systems used in GMP-regulated activities, broader in scope and more explicit about the system lifecycle, risk management and suppliers. Where they overlap, satisfy the stricter requirement. Where only one applies, satisfy that one.
Scope
Part 11 is about electronic records and signatures: when they are trustworthy, and when they are equivalent to paper and handwriting. Annex 11 is about the computerised system as a whole, its validation, operation, data, security, and the relationship with the supplier that provides it. In practice Annex 11 reaches wider: it expects a validated system lifecycle and a documented risk assessment, not just compliant records.
Where they align
| Theme | Both require |
|---|---|
| Audit trails | Secure, time-stamped, computer-generated records of changes that do not obscure prior data. |
| Electronic signatures | Attributable signatures tied to their records, showing who, when and the meaning. |
| Access control | Access limited to authorised users, with individual accountability and no shared logins. |
| Data integrity | Records protected, accurately retrievable, and secured against unauthorised change. |
| Copies | The ability to produce readable copies of records for the inspector. |
Where they differ
- Lifecycle and validation. Annex 11 is explicit about a validated system lifecycle, change control and periodic review. Part 11 assumes validation but says less about the surrounding lifecycle.
- Risk management. Annex 11 requires a documented risk-management approach across the system lifecycle. Part 11 does not use the same explicit risk framing.
- Suppliers and service providers. Annex 11 expects formal agreements and assessment of suppliers and any service provider. Part 11 does not address this directly.
- Signature meaning. Part 11 is very specific about signature components and the linkage of signature to record. Annex 11 treats signatures within the broader data-integrity expectations.
If you need both
Most global operations do. The practical approach is to design one system that meets the stricter requirement on each theme:
- 1Build Part 11 grade electronic signatures: two-component signing, bound to the record state, permanently linked to the record.
- 2Build Annex 11 grade lifecycle: documented validation, change control, periodic review and a risk assessment for the system.
- 3Enforce audit trails and access control that satisfy both: immutable, attributable, individual.
- 4Keep supplier and service agreements that satisfy Annex 11, even for a US-first deployment.
- 5Generate inspection copies that work for either an FDA or an EU inspector.
Frequently asked questions
No. They pursue the same goal, trustworthy computerised systems and electronic records, but Part 11 is a US FDA regulation focused on electronic records and signatures, while EU GMP Annex 11 is a broader European guideline covering the whole system lifecycle, risk management and suppliers. A system compliant with one is not automatically compliant with the other.